login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
AMYLYX PHARMACEUTICALS INC (AMLX) Stock News
USA
-
Nasdaq
- NASDAQ:AMLX -
US03237H1014
-
Common Stock
14.24
USD
0 (0%)
Last: 12/2/2025, 9:41:18 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
AMLX Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Halper Sadeh LLP
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
15 days ago - By: The Motley Fool
- Mentions:
ABVX
CGON
COGT
CNTA
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead
15 days ago - By: The Motley Fool
- Mentions:
LQDA
ABVX
CGON
COGT
...
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch
a month ago - By: Benzinga
- Mentions:
STVN
PODD
AMRK
SOLV
...
Earnings Scheduled For November 6, 2025
3 months ago - By: Stocktwits
Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder
4 months ago - By: Benzinga
- Mentions:
GSAT
PGY
ADV
REAL
...
Earnings Scheduled For August 7, 2025
19 days ago - By: The Rosen Law Firm, P.A.
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
21 days ago - By: Rosen Law Firm
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
22 days ago - By: Zacks Investment Research
- Mentions:
EXAS
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?
26 days ago - By: Grabar Law Office
- Mentions:
AVTR
HUM
MSS
Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf
a month ago - By: Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
a month ago - By: Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
a month ago - By: Grabar Law Office
- Mentions:
FIVE
HUM
TMCI
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf
a month ago - By: Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
a month ago - By: Halper Sadeh LLC
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
a month ago - By: Zacks Investment Research
What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now?
a month ago - By: Grabar Law Office
- Mentions:
BAX
HUM
FIVE
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office Investigates Claims on Your Behalf
a month ago - By: Kuehn Law, PLLC
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
a month ago - By: Grabar Law Office
- Mentions:
BAX
FIVE
HUM
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf
2 months ago - By: Grabar Law Office
- Mentions:
HUM
FIVE
HTZ
Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
2 months ago - By: Bragar Eagel & Squire
AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders
2 months ago - By: Grabar Law Office
- Mentions:
HUM
FIVE
TMCI
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf
2 months ago - By: Grabar Law Office
- Mentions:
FIVE
HUM
TMCI
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf
2 months ago - By: Grabar Law Office
- Mentions:
HUM
FIVE
VSTS
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf
2 months ago - By: Grabar Law Office
- Mentions:
VSTS
HUM
UNCY
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf
2 months ago - By: Kuehn Law, PLLC
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
3 months ago - By: Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
3 months ago - By: Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
3 months ago - By: Stocktwits
- Mentions:
IWMW
VTWG
BAC
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
3 months ago - By: Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
3 months ago - By: Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
4 months ago - By: Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
4 months ago - By: Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
Please enable JavaScript to continue using this application.